Provided by Tiger Trade Technology Pte. Ltd.

Bioxcel Therapeutics Inc.

0.1628
-0.0186-10.25%
Post-market: 0.1554-0.0074-4.55%16:54 EDT
Volume:10.54M
Turnover:1.68M
Market Cap:5.10M
PE:-0.05
High:0.1700
Open:0.1509
Low:0.1415
Close:0.1814
52wk High:4.29
52wk Low:0.1415
Shares:31.31M
Float Shares:26.89M
Volume Ratio:0.83
T/O Rate:39.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1505
EPS(LYR):-5.7255
ROE:-1766.94%
ROA:-102.43%
PB:-0.04
PE(LYR):-0.03

Loading ...

BioXcel Therapeutics - Required to Enter Agreements by August 21, 2026, to Repay Obligations or Pursue Alternative Capital Solutions - SEC Filing

THOMSON REUTERS
·
Aug 11

BioXcel Therapeutics - Enters Twelfth Amendment to Credit Agreement on August 10, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 11

BioXcel Therapeutics - Lenders Reduce Minimum Liquidity Covenant to $3 Mln from $6.25 Mln - SEC Filing

THOMSON REUTERS
·
Aug 11

BioXcel Therapeutics Inc Expected to Post a Loss of 51 Cents a Share - Earnings Preview

Reuters
·
Aug 07

BioXcel Therapeutics Amends Oaktree-Led Credit Agreement, Defers Loan Payment to Aug. 31

Reuters
·
Aug 03

BioXcel Therapeutics - Lenders Defer Principal Payment to August 31, 2026; $9.02 Mln Plus Accrued Interest Due - SEC Filing

THOMSON REUTERS
·
Aug 03

BioXcel Therapeutics - Company Required to Enter Definitive Agreements by August 10, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 03

Bioxcel Therapeutics Forms Strategic Committee to Weigh Restructuring, Bankruptcy Options Under Oaktree Loan Amendment

Reuters
·
Jul 06

BioXcel Therapeutics posts new Phase 3 SERENITY At-Home data for BXCL501 in agitation linked to bipolar disorder, schizophrenia

Reuters
·
May 28

BioXcel Therapeutics Presents New Data From Serenity at-Home Phase 3 Trial for Agitation Associated With Bipolar Disorders or Schizophrenia at 2026 Ascp Annual Meeting

THOMSON REUTERS
·
May 28

BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

BioXcel net loss widens to $12.69 million in Q1 FY26

Reuters
·
May 15

BioXcel Therapeutics Inc - FDA Accepts Igalmi at-Home Snda; Pdufa Date Set for Nov 14, 2026

THOMSON REUTERS
·
May 15

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 11

BioXcel Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 08

BioXcel Therapeutics issues warrants for 1,353,729 shares at $0.01 exercise price

Reuters
·
Apr 18

BioXcel Therapeutics to host virtual event on IGALMI at-home launch plan

Reuters
·
Apr 17

BUZZ-U.S. STOCKS ON THE MOVE-Delta, GATX, Humana

Reuters
·
Apr 08

BUZZ-BioXcel rises as trial starts for its stress disorder drug in trauma victims

Reuters
·
Apr 08